-- RBCキャピタル・マーケッツは木曜日のレポートで、ドーバー（DOV）の第1四半期決算が予想をやや上回り、受注高は24%増、受注高対売上高比率は1.20倍となり、需要の勢いを示していると述べた。 RBCは、受注高の好調は幅広い分野に及び、すべてのセグメントで受注高対売上高比率が1.10倍を超えたと指摘した。 RBCは、クリーンエネルギー部品、流体輸送、小売燃料供給、冷蔵ドアケース、熱交換器、CO2冷凍システムの好調を特に強調した。 また、RBCは、受注高の好調は、ドーバーの3%～5%のオーガニック成長率ガイダンスの上方修正を示唆していると述べた。ドーバーは、2026年の調整後1株当たり利益ガイダンスを10.45ドル～10.65ドル、売上高成長率見通しを5%～7%と再確認した。 RBCは、ドーバーの目標株価を225ドルから252ドルに引き上げ、セクター・パフォームの投資判断を維持した。
Price: $229.96, Change: $+1.81, Percent Change: +0.79%
Oneview Healthcare (ASX:ONE) reported cash receipts from customers of about 3.3 million euros for the first quarter, compared with 4.2 million euros a year earlier, according to a Monday filing with the Australian bourse.The company noted that the year-ago figure includes two large customer receipts totaling more than 2 million euros, which were due to be received during the fourth quarter of 2024 but were received in early 2025.Oneview Healthcare ended March with a cash balance of AU$17.1 million, up from AU$8.1 million at the close of 2025, per the filing.The company's shares gained 3% in recent Monday trade.
Paradigm Biopharmaceuticals (ASX:PAR) is set to progress participants through the day 112 follow-up period for the phase three trial evaluating injectable pentosan polysulfate sodium for the treatment of pain associated with knee osteoarthritis in the June quarter, which is required for inclusion in the interim analysis dataset, according to a Monday Australian bourse filing.The independent statistical analysis results for the data set are expected around August. Timing remains subject to the scheduling and review processes of independent third parties, and there is a reasonable likelihood that final interim outcomes may extend into September, it cautioned.The interim analysis is expected to provide the first phase three evaluation of efficacy and safety for injectable pentosan polysulfate sodium in knee osteoarthritis. Primary endpoint top-line results are expected in the March 2027 quarter.Its shares fell 14% in recent trading on Monday, reaching their lowest point in over a year.
Sanan Optoelectronics (SHA:600703) posted first-quarter attributable net profit of 67.5 million yuan, down 68% from 211.9 million yuan the previous year.Earnings per share declined to 0.01 yuan from 0.04 yuan, according to a weekend filing with the Shanghai bourse.Operating revenue declined 33% year over year to 2.91 billion yuan from 4.31 billion yuan.Shares of the software company declined 2% in recent trade.